A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).

Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, Kondo T, Tsuchida K, Atsumi T, Manda N, Kurihara Y, Aoki S

PloS one18 Aug 2015Cited by 38 (Europe PMC)

PMID26284918PMCIDPMC4540491DOI10.1371/journal.pone.0135854PepBankPUB-26284918

Download PDF PubMedAsk about this study

Jump to 11 results

Summary

ObjectivesGLP-1 improves hyperglycemia, and it has been reported to have favorable effects on atherosclerosis. However, it has not been fully elucidated whether GLP-1 is able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of the GLP-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy.Materials and methodsIn this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks. Flow mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force Monitor), and serum metabolic markers were assessed before and after the treatment period.ResultsA greater reduction (worsening) in %FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4%, glargine 6.7 to 5.7%). The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group. Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different.ConclusionsRegardless of glycemic improvement, early liraglutide therapy did not affect endothelial function but may provide favorable effects on beta-cell function and cardioprotection in type 2 diabetics without advanced atherosclerosis.Trial registrationUMIN Clinical Trials Registry System as trial ID UMIN000005331.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the change in %FMD with liraglutide did not differ significantly from glargine (liraglutide 5.7 to 5.4%, glargine 6.7 to 5.7%).
In plain wordsIn adults with type 2 diabetes, blood vessel dilation did not differ significantly between liraglutide and insulin glargine.
Peptide
Liraglutide
Outcome
No significant changeFlow mediated dilation (%FMD)
Study
n = 31
Comparator
Insulin glargine
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Measurements
%FMD before
5.7%
liraglutide
%FMD after
5.4%
liraglutide
Source sentences
Summary
A greater reduction (worsening) in %FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4%, glargine 6.7 to 5.7%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491801
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the augmentation index was significantly improved in the liraglutide group.
In plain wordsIn adults with type 2 diabetes, a measure of artery stiffness improved with liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedAugmentation index
Study
n = 31
Comparator
Insulin glargine
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491802
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the C-peptide index was significantly improved in the liraglutide group.
In plain wordsIn adults with type 2 diabetes, a measure of insulin-producing cell function improved with liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedC-peptide index
Study
n = 31
Comparator
Insulin glargine
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491803
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, derivatives of reactive oxygen metabolites were significantly improved in the liraglutide group.
In plain wordsIn adults with type 2 diabetes, a marker of oxidative stress improved with liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedDerivatives of reactive oxygen metabolites
Study
n = 31
Comparator
Insulin glargine
Outcome group
Inflammation markers · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491804
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, BMI was significantly improved in the liraglutide group.
In plain wordsIn adults with type 2 diabetes, BMI improved with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBMI
Study
n = 31
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491805
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, central systolic blood pressure tended to be improved in the liraglutide-treated group.
In plain wordsIn adults with type 2 diabetes, central blood pressure tended to improve with liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedCentral systolic blood pressure
Study
n = 31
Comparator
Insulin glargine
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491806
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, NT-proBNP tended to be improved in the liraglutide-treated group.
In plain wordsIn adults with type 2 diabetes, a heart strain marker tended to improve with liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedNT-proBNP
Study
n = 31
Comparator
Insulin glargine
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491807
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, improvements in HbA1c were similar between the liraglutide and glargine groups.
In plain wordsIn adults with type 2 diabetes, HbA1c improved by a similar amount with liraglutide and with insulin glargine.
Peptide
Liraglutide
Outcome
No significant changeHbA1c improvement
Study
n = 31
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491808
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, cardiac index did not differ between liraglutide and glargine.
In plain wordsIn adults with type 2 diabetes, cardiac index did not differ between liraglutide and insulin glargine.
Peptide
Liraglutide
Outcome
No significant changeCardiac index
Study
n = 31
Comparator
Insulin glargine
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Cardiac index, blood pressure and most other metabolic parameters were not different.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491809
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, blood pressure did not differ between liraglutide and glargine.
In plain wordsIn adults with type 2 diabetes, blood pressure did not differ between liraglutide and insulin glargine.
Peptide
Liraglutide
Outcome
No significant changeBlood pressure
Study
n = 31
Comparator
Insulin glargine
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Cardiac index, blood pressure and most other metabolic parameters were not different.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491810
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, most other metabolic parameters did not differ between liraglutide and glargine.
In plain wordsIn adults with type 2 diabetes, most other metabolic measures did not differ between liraglutide and insulin glargine.
Peptide
Liraglutide
Outcome
No significant changeMost other metabolic parameters
Study
n = 31
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 14 weeksAs given in this study (human).
Source sentences
Summary
Cardiac index, blood pressure and most other metabolic parameters were not different.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks.
Show in the study text Report a problemFND-2628491811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.